Submit an Article > Register > Login >

Annali

dell'Istituto Superiore di Sanità

Search
Vol. 56 No. 3 (2020)
Original Articles
2020-09-11
Share on

Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?

Authors

Loreta A. Kondili , Sarah Blach , Homie Razavi , Antonio Craxi

Keywords: hepatitis C, infection, WHO elimination goal

Abstract

Background and aims. Hepatitis C virus (HCV) elimination for Italy is an ambitious,
but achievable goal. In Italy, there is political will, which aims to achieve the World Health
Organization (WHO) elimination goals recognizing the need to identify undiagnosed individuals in key high-risk groups and in the general population, however there is concern
regarding HCV treatment implementation in Italian Regions.
Methods. A modelling analysis was conducted, using the “Italy Polaris” model, to forecast
the impact of different HCV treatment rates in achieving the HCV elimination goals in
Italy. The model assessed two treatment scenarios: 2018 Scenario and 2019 Scenario, using
the annually HCV treatment rate in Italy.
Results. Considering a high treatment rate, as assumed by the 2018 Scenario, all HCV
elimination targets would be achieved. Considering the 2019 Scenario, in which a decreasing
number of newly diagnosed individuals and as consequence, a decline in the
number of treated patients, were assumed, only the 65% HCV mortality reduction would
be an achievable goal in Italy. The other elimination targets could be achievable over 7
years later than the year 2030.
Conclusions. Establishing an ad hoc fund for DAAs for each Italian Region, binding resources
both for case finding, through active screening and activities for rapid linkage to
care and treatment, is of paramount importance, in order to keep Italy on track to achieve
the WHO elimination targets by 2030.

References

  1. References
  2. WHO. Global Health Sector Strategy on Viral Hepatitis, 2016–2021 Towards Ending Viral Hepatitis. 2016, World Health Organization.
  3. The Italian Medicines Agency http://www.agenziafarmaco.gov.it/content/registri-farmaci-sottoposti-monitoraggio.
  4. Kondili LA, Robbins S, Blach S et al. Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
  5. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014; 21 (Suppl 1): 34-59.
  6. Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet GastroenterolHepatol. 2016; 2: 161-76.
  7. Andriulli A, Stroffolini T, Mariano A, et al. Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: a population- based survey. Eur J Intern Med. 2018; 53: 79-84.
  8. Razavi H, Sanchez- Gonzales Y, Yuen C, Cornberg M, Global timing of hepatitis C virus elimination in high-income contries. Liver International. 2019; 00: 1-8. https://doi.org/10.1111/liv.14324.
  9. CDA Foundation’s Polaris Observatory, Italy Progress Toward Elimination 2019. 2020 (updated) Available from https://cdafound.org/polaris/. (Accessed March 26, 2020).
  10. . Deuffic-Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries.Gastroenterology. 2012;143:974–985.
  11. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26:1006–101
  12. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci. 2012; 16:1473–1483.
  13. Kondili LA, Gamkrelidze I Blach S, et al. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International 2020 (In press) https://doi.org/10.1111/liv.14408
  14. Kondili LA, Andreoni M, Alberti A. Estimated prevalence of undiagnosed hepatitis C virus infected individuals in Italy: a mathematic model to accurately measure HCV prevalence with a route of transmission granularity. Hepatology. October 2019; 70 (S1) AASLD abstract (poster) N.0520 Friday 8 November 2020: p328A
  15. Negro F, Forton D, Craxì A et al Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015 Nov;149(6):1345-60
  16. Adinolfi LE, Petta S, Fracanzani AL et al Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis. 2020 Mar; 296:40-47.
  17. .Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS. Economic consequences of investing in anti-HCV antiviral treatment from the Italian NHS perspective: a real-world-based analysis of PITER data. Pharmacoeconomics. 2019;37:255-266.
  18. Legislative Decree No. 8, 28 Febbruary2020. Article 25 sexies - Screening nazionale gratuito per l’eliminazione del virus HCV (Gazzetta Ufficiale della Repubblica Italiana n. 51 del 29.02.20, Supplemento ordinario n. 10)

Downloads

PDF
Authors

Loreta A. Kondili - National Center for Global Health Istituto Superiore di Sanità Viale Regina Elena 299 00161 Rome, Italy https://orcid.org/0000-0003-2656-224X

Sarah Blach

Homie Razavi

Antonio Craxi

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite
Kondili, L. A., Blach, S., Razavi, H., & Craxi, A. (2020). Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?. Annali dell’Istituto Superiore Di Sanità, 56(3), 325–329. Retrieved from https://annali.iss.it/index.php/anna/article/view/1055
  • Abstract viewed - 560 times
  • PDF downloaded - 187 times